ã¯ãããã®ãããªå£°æã¯ããªããé©ããããããããŸãããã¯ã¯ãã³ã¯äººã®æã«æ³šå ¥ãããæ¶²äœã§ãããœãŒã¹ã³ãŒãã¯ãããšäœã®é¢ä¿ããããŸããïŒ
è¯ã質åããŸããBioNTech / Pfizerã¯ã¯ãã³ã®åããœãŒã¹ã³ãŒãã®ããäžéšããå§ããŸããããã¯ãBNT162b2ãšãåŒã°ãã TozinameranãšãåŒã°ããComirnatyãšãåŒã°ã ãŸãã
BNT162b2mRNAã®æåã®500æåã
ã¯ã¯ãã³ã®äžå¿ã¯ãã®ããžã¿ã«ã³ãŒãã§ãããã®é·ãã¯4284æåãªã®ã§ãããã€ãã®ãã€ãŒãã«åãŸããŸããã¯ã¯ãã³è£œé ããã»ã¹ã®æåã®æ®µéã§ã誰ãããã®ã³ãŒããDNAããªã³ã¿ãŒã«ã¢ããããŒããïŒããïŒããããã¹ãã¬ãŒãžããã€ã¹ããã®ãã€ããå®éã®DNAååã«å€æããŸããã
DNAããªã³ã¿ãŒCodexDNA BioXp 3200
ãã®ãããªæ©æ¢°ãããå°éã®DNAãçŸããŸããããã¯ãé·æã«ãããçç©åŠçããã³ååŠçåŠçã®åŸãã¯ã¯ãã³ãå ¥ã£ããã€ã¢ã«å ã§RNAã«å€ãããŸãã 30ÎŒgã®çšéã«ã¯å®éã«ã¯30ÎŒgã®RNAãå«ãŸããŠããŸãããŸããmRNAã现èã«ééããå·§åŠãªè質ïŒèèªïŒããã±ãŒãžã³ã°ã·ã¹ãã ãåããŠããŸãã
RNAã¯ããäœæ¥ã¡ã¢ãªãŒãã«ä¿åãããŠãããããæ®çºæ§ããŒãžã§ã³ã®DNAã§ãã DNAã¯çç©åŠã®ãã©ãã·ã¥ãã©ã€ãã®ãããªãã®ã§ãã DNAã¯ä¿¡é Œæ§ãé«ããå ç¢ã§ãå éšçã«åé·ã§ãããã ããã³ã³ãã¥ãŒã¿ãŒã¯ãã©ãã·ã¥ãã©ã€ãããçŽæ¥ã³ãŒããå®è¡ããããšããããŸããããã¹ãŠãéå§ãããåã«ãã³ãŒãã¯ããé«éã§æè»æ§ããããããã«è匱ãªã·ã¹ãã ã«ã³ããŒãããŸãã
ã³ã³ãã¥ãŒã¿ãŒã§ã¯ããã¯RAMã§ãããçç©åŠã§ã¯RNAã§ããé¡äŒŒæ§ã¯è¡æçã§ãããã©ãã·ã¥ã¡ã¢ãªãšã¯ç°ãªããRAMã¯æ³šææ·±ãæå ¥ãããªããšããã«å£åããŸããPfizer / BioNTech RNAã¯ã¯ãã³ãéåžžã«äœæž©ã§ä¿ç®¡ããå¿ èŠãããçç±ã¯ åãã§ããã€ãŸããRNAã¯ç¹çްãªè±ã§ãã
åRNAã·ã³ãã«ã¯ã0.53Ã10ã®é ã«é -21ã30ÎŒgã®ã¯ã¯ãã³ã®çšéã¯6Ã10å«ãŸããŠããã°ã©ã ã 16ã·ã³ãã«ããå®éãã¯ã¯ãã³ã¯åã4284æåã®2000ååã®ç¹°ãè¿ãã§æ§æãããŠããŸããããã€ãåäœã§ã¯ãããã¯çŽ25PBã«ãªããŸããã¯ã¯ãã³ã®å®éã®å«æéã¯1ãããã€ã匷ã§ããSARS-CoV-2èªäœã®ããªã¥ãŒã ã¯çŽ7.5KBã§ãã
ã¯ã€ãã¯ãªãã¡ã¬ã³ã¹
DNAã¯ããžã¿ã«ã³ãŒãã§ãããã ãã0ãš1ã䜿çšããã³ã³ãã¥ãŒã¿ãŒãšã¯ç°ãªããæåAãCãGãããã³U / TïŒããã¯ã¬ãªããããããã¯ã¬ãªã·ããããŸãã¯ãå¡©åºãïŒã䜿çšããŸãã
ã³ã³ãã¥ãŒã¿ã§ã¯ã0ãš1ã¯ãé»è·ã黿µãç£æ°æ¥åãé»å§ãä¿¡å·å€èª¿ããŸãã¯åå°çã®å€åã®æç¡ã®åœ¢ã§ä¿åãããŸããèŠããã«ã0ãš1ã¯æœè±¡åã§ã¯ãªããé»åãä»ã®å€ãã®ç©ççãªå身ã®åœ¢ã§çããŠããŸãã
èªç¶çã§ã¯ãAãCãGãããã³U / Tã¯ãéç¶ã®DNAïŒãŸãã¯RNAïŒã«æ ŒçŽãããŠããååã§ãã
ã³ã³ãã¥ãŒã¿ãŒã§ã¯ã8ãããããã€ãã«ã°ã«ãŒãåãããããŒã¿ã¯éåžžãã€ãåäœã§åŠçãããŸãã
èªç¶ã¯3ã€ã®ãã¯ã¬ãªãããã³ãã³ã«ã°ã«ãŒãåããŸã ãéºäŒæ å ±ãåŠçããããã®å žåçãªåäœã§ããã³ãã³ã«ã¯6ãããã®æ å ±ãå«ãŸããŠããŸãïŒDNAã·ã³ãã«ããšã«2ãããã3æå= 6ãããïŒãããã¯ãã³ãã³ã2 6 = 64ã®ç°ãªãå€ãåãããšãã§ããããšãæå³ã ãŸãã
ãããŸã§ã®ãšããããã¹ãŠãããªãããžã¿ã«ã§ããçããã人ã¯ãããžã¿ã«ã³ãŒããå«ãWHOã®ããã¥ã¡ã³ããèŠãããšãã§ããŸã ã
ã§ã¯ããã®ã³ãŒãã¯äœãããã®ã§ããããïŒ
ã¯ã¯ãã³ã®èåŸã«ããèãæ¹ã¯ãå®éã«ç æ°ã«ãªãããšãªãç åäœãšæŠãããã«å ç«ã·ã¹ãã ã«æããããšã§ããæŽå²çã«ãããã®ããã«ãå ç«ç³»ãé©åã«æŽ»æ§åããããã匷å¶çã«äœçšãããããã«ã匱äœåããããŸãã¯æ©èœããªããŠã€ã«ã¹ããè£å©å€ãåããäœå ã«å°å ¥ããããäœååãã®åµïŒãŸãã¯æè«ïŒã䜿çšããã®ã¯äž»ã«ã¢ããã°æè¡ã§ããã圌女ã¯ãŸããå€ãã®éãšå€ãã®æéãå¿ èŠãšããŸãããããã«ã¯ããŸã£ããç°ãªããŠã€ã«ã¹ã䜿çšãããããšããããŸããã
mRNAã¯åãçµæïŒå ç«ã·ã¹ãã ã®ãã¬ãŒãã³ã°ïŒãéæããŸãããã¬ãŒã¶ãŒãµã€ãã䜿çšããå Žåãšåãããã«ã¯ããã«ã¹ããŒãã§ãããã¹ãŠã®æå³ã§-çŠç¹ãçµãããŠããŸããã匷åãªåœ±é¿ããããŸãã
ä»çµã¿ã¯æ¬¡ã®ãšããã§ãããã®è£œå€ã«ã¯ãæåãªã¿ã³ãã¯è³ªãã¹ãã€ã¯ãSARS-CoV-2ã説æããäžå®å®ãªéºäŒç©è³ªãå«ãŸããŠããŸããå·§åŠãªååŠåå¿ãéããŠãã¯ã¯ãã³ã¯ãã®éºäŒç©è³ªãç§ãã¡ã®çްèã®ããã€ãã«å±ããŸãã
ãã®åŸããããã¯çŽ çŽã«SARS-CoV-2ã¿ã³ãã¯è³ªãçæãå§ããŸãããã®éã¯ç§ãã¡ã®å ç«ã·ã¹ãã ãéå§ããã®ã«ååãªéã§ããã¹ãã€ã¯ã¿ã³ãã¯è³ªãšçŽ°èææã®ç¹åŸŽçãªå åã«çŽé¢ããŠãã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ããŸããŸãªç¹æ§ãšãã®åçããã»ã¹ã«å¯ŸããŠåŒ·åãªå¿çã瀺ããŸãã
ããã¯ãã¯ã¯ãã³ã95ïŒ ã®å¹æã§ã©ã®ããã«æ©èœãããã§ãã
ãœãŒã¹ïŒ
æé«ã®å Žæããå§ããŸããã-æåãããWHOããã¥ã¡ã³ãã«ã¯ã次ã®åœ¹ç«ã€å³ããããŸãã
ããã¯äžçš®ã®ã³ã³ãã³ãã§ããåžœåã®åœ¢ã§ãã¶ã€ã³ãããããã£ãããã¢ã€ãã ããå§ããŸããã[engããã£ãã-ãã£ããããã£ãããåžœå]ã
ã³ã³ãã¥ãŒã¿ãŒã®å Žåãšåãããã«ãopcodeããã¡ã€ã«ã«æžã蟌ãã§å®è¡ããã ãã§ã¯äžååã§ããçç©åŠçãªãã¬ãŒãã£ã³ã°ã·ã¹ãã ã«ã¯ãããããŒããªã³ã«ãŒãããã³å€æ°ã®åœåèŠåãªã©ãå¿ èŠã§ãã
ã¯ã¯ãã³ã³ãŒãã¯ã次ã®2ã€ã®ãã¯ã¬ãªããã§å§ãŸããŸãã
GA
ãMZãæåã§å§ãŸãDOSããã³Windowså®è¡å¯èœãã¡ã€ã«ããŸãã¯ãïŒïŒãã§å§ãŸãUNIXã¹ã¯ãªããã«çžåœããŸããçæŽ»ãšãªãã¬ãŒãã£ã³ã°ã·ã¹ãã ã®äž¡æ¹ã§ããããã®2ã€ã®æåã¯å®è¡ãããŸããããããããããã¯ããã«ãªããã°ãªããŸãããããã§ãªããã°ãäœãæ©èœããŸããã
mRNAããããŒã«ã¯ããã€ãã®æ©èœããããŸãã圌女ã¯ãããšãã°ãã³ãŒãã¯ã«ãŒãã«ããã®ãã®ã§ãããšè¿°ã¹ãŠããŸããç§ãã¡ã®å Žåãããã¯åœãŠã¯ãŸããŸãã-ã³ãŒãã¯åœç¶ã¯ã¯ãã³ããæ¥ãŠããŸããããããã»ã«ã¯ãããç¥ãå¿ èŠã¯ãããŸãããåžœåã¯ã³ãŒãã«ä¿¡é Œæ§ãäžããç Žå£ããä¿è·ããŸãã
ãŸãã2ã€ã®å ã®GAãã¯ã¬ãªããã¯ãæ®ãã®RNAãšã¯ååŠçã«ãããã«ç°ãªããŸãããã®æå³ã§ãäžçš®ã®åž¯åå€ã·ã°ããªã³ã°ãGAã«çµã¿èŸŒãŸããŠããŸãã
5å°ç¯ã®ç¿»èš³ãããŠããªãå°å
ã¡ãã£ãšããå°éçšèªãRNAååã¯äžæ¹åã«ã®ã¿èªã¿åãããŸããå°ãçŽããããã®ã¯ãèªã¿åãã5 'ãšåŒã°ããéšåããå§ãŸãããš ã§ãããããŠããŒã3 'ã§çµãããŸãã
çåœã¯ã¿ã³ãã¯è³ªïŒãããŠãããã§ã§ããŠãããã¹ãŠã®ãã®ïŒã§ã§ããŠããŸãããããã®ã¿ã³ãã¯è³ªã¯RNAã«èšèŒãããŠããŸããRNAããã¿ã³ãã¯è³ªãžã®å€æã¯ç¿»èš³ãšåŒã° ããŸãã
次ã«ã é翻蚳é åïŒUTR;é翻蚳é åãUTRïŒ5 'ãæå®ããŸããã€ãŸãããã®éšåã¯ã¿ã³ãã¯è³ªã«æž¡ãããŸããã
GAAΚAAACΚAGΚAΚΚCΚΚCΚGGΚCCCCACAGACΚCAGAGAGAACCCGCCACC
ããã§ç§ãã¡ã¯æåã®é©ãã«åãã£ãŠããŸãã RNAã®éåžžã®èšå·ã¯AãCãGãUã§ããDNAã§ã¯ãUã¯TãšããŠãç¥ãããŠããŸããããããããçš®ã®ÎšãçŸããŸã-ã©ããªããŸããïŒ
ããã¯ãã¯ã¯ãã³ã®éåžžã«ããªãããŒãªç¹æ§ã®1ã€ã§ããç§ãã¡ã®äœã«ã¯åŒ·åãªæãŠã€ã«ã¹ã·ã¹ãã ããããŸãã圌女ã®ãããã§ã现èã¯å€æ¥RNAã«éåžžã«æççã§ãããäœããããåã«ããããç Žå£ããããšæžåœã«åªåããŸãã
ããã¯ã¯ã¯ãã³ã®åé¡ã§ã-ããã¯ç§ãã¡ã®å ç«ã·ã¹ãã ãããæããå¿ èŠããããŸããé·å¹Žã®å®éšã§ãRNAã®Uããããã«å€åããååã«çœ®ãæãããããšãå ç«ç³»ã¯ããã«èå³ã倱ãããšãããããŸããããŸã£ããã
ãããã£ãŠãBioNTech / Pfizerã¯ã¯ãã³ã§ã¯ãåUã1-ã¡ãã«-3'-ã·ã¥ãŒããŠãªãžã³ã«çœ®ãæããããŸãã ãããã¯Îšã§è¡šãããŸããããã§ã®ç§èš£ã¯ããã®ãããªçœ®æãå ç«ç³»ãé®éåãããã现èã®å¿ èŠãªéšåããããéåžžã®UãšããŠèªèããããšã§ãã
ãã®ç§èš£ã¯ã³ã³ãã¥ãŒã¿ãŒã®ã»ãã¥ãªãã£ã§ãç¥ãããŠããŸãããã¡ã€ã¢ãŠã©ãŒã«ãšã»ãã¥ãªãã£ã·ã¹ãã ãæ··ä¹±ãããããããã«æååãããããŒãžã§ã³ã®ã¡ãã»ãŒãžãéä¿¡ã§ããå ŽåããããŸãããããã¯ãšã³ããµãŒããŒã§ã¯åãå ¥ããããŸãããããŠããããã¯ãããã³ã°ãããå¯èœæ§ããããŸãã
仿¥ãç§ãã¡ã¯éå»ããã®åºç€çãªç§åŠçç ç©¶ã®ææã享åããŠããŸãã ãã®Îšãã¯ãããžãŒã çºèŠãã人ã ã¯ãè³éãèŠã€ããŠèªç¥ãåŸãããã«æŠããªããã°ãªããŸããã§ãããç§ãã¡ã¯åœŒãã«æè¬ãã¹ãã§ãããããŒãã«è³ã¯æçµçã«åœŒããèŠã€ãããšç¢ºä¿¡ããŠã ãŸãã
, Κ-, ? , . , 1--3'-. , , . , Κ .
5ãã£ãŒãã®NTOã«æ»ããŸãããããããã®51ã®ã·ã³ãã«ã¯äœãããŸããïŒèªç¶çã®ã»ãšãã©ãã¹ãŠã®ããã«ããããã¯åäžã®æç¢ºãªæ©èœãæã£ãŠããŸããã
现èãRNAãã¿ã³ãã¯è³ªã«å€æããå¿ èŠãããå ŽåããªããœãŒã ãšåŒã°ããæ©æ¢°ããªã³ã«ãªããŸãããªããœãŒã ã¯ã¿ã³ãã¯è³ªã®3Dããªã³ã¿ãŒã®ãããªãã®ã§ããããã¯RNAã®äžéšãåžåããããã«åºã¥ããŠã¢ããé žã®éãæŸåºããããã ã¿ã³ãã¯è³ªã«æããããŸããŸãã
ãã®ããã»ã¹ã¯ãããªã§ç€ºãããŠããŸããäžã®æ¿ãçžã¯RNAã§ããç·ã®èæ¯ã®çžæš¡æ§ã圢æã¿ã³ãã¯è³ªã§ããã€ã³ããŠã³ããšã¢ãŠãããŠã³ãã®ã®ãºã¢ã¯ãRNAã«é©åãããããã®ã¢ããé žãš ã¢ããã¿ãŒã§ãã
ãªããœãŒã ãæ©èœããããã«ã¯ãRNAã®äžéšã«ç©ççã«åº§ã£ãŠããå¿ èŠããããŸãããã®åŸããããªãRNAã»ã°ã¡ã³ãããã®æ å ±ã«åºã¥ããŠã¿ã³ãã¯è³ªã®åœ¢æãéå§ã§ããŸããã€ãŸããæåã«çéžããå¿ èŠã®ããéšåãèªã¿åãããšãã§ããŸããã ãã¬ã€ãã³ã¹ãã¯NTOã«ãã£ãŠæäŸãããŸãã
ããã«ãNTOã«ã¯ã¡ã¿ããŒã¿ãå«ãŸããŠããŸãããããŒããã£ã¹ãã¯ãã€è¡ãå¿ èŠããããŸããïŒãããïŒã¯ã¯ãã³ã«ã€ããŠã¯ãç§åŠè ãã¡ã¯æŸéã³ãã³ããã§ããã ãæ©ãèšé²ãããNTOãèŠã€ããŸããã圌女ã¯ããæ¥ã éºäŒåã¢ã«ãã¡ã°ããã³ããã®éºäŒåã¯ã倧éã®ã¿ã³ãã¯è³ªã確å®ã«çæããããšã§ç¥ãããŠããŸããéå»ã«ãç§åŠè ã¯ãã®UTRãããã«æé©åããæ©äŒããã§ã«èŠã€ããŠãããããã¯ã¯ãã³ã«ã¯ã¢ã«ãã¡ã°ããã³ããã®UTRã䜿çšããªããªããŸããããããåªãããã®ã䜿çšããŸããã
S-ç³ã¿ã³ãã¯è³ªã·ã°ãã«é å
åè¿°ã®ããã«ãã¯ã¯ãã³ã®ç®æšã¯ã现èã«SARS-CoV-2ã¹ãã€ã¯ã¿ã³ãã¯è³ªãå·¥æ¥èŠæš¡ã§çç£ãããããšã§ãããããŸã§ããœãŒã¹ã³ãŒãã§ã¡ã¿ããŒã¿ãšåœåèŠåãäž»ã«æ±ã£ãŠããŸããããããŠä»ãç§ãã¡ã¯ãŠã€ã«ã¹ã¿ã³ãã¯è³ªã®é åã«å ¥ã£ãŠããŸãã
ãã ããæåã«ã¡ã¿ããŒã¿ã®å¥ã®ã¬ã€ã€ãŒãééããå¿ èŠããããŸãããªããœãŒã ïŒäžèšã®çŽ æŽãããã¢ãã¡ãŒã·ã§ã³ããïŒãã¿ã³ãã¯è³ªãäœã£ãåŸãããã¯ãŸã ã©ããã«å°éããå¿ èŠããããŸããããã¯ãS-ç³ã¿ã³ãã¯è³ªã®ã·ã°ãã«é åïŒããããïŒ ïŒæ¡åŒµ ãªãŒããŒé åïŒã«ã³ãŒãåãããŠã ãŸãã
ã¿ã³ãã¯è³ªã®æåã«ã¯ãã¿ã³ãã¯è³ªå šäœãšåã圢åŒã§ãšã³ã³ãŒããããã¢ãã¬ã¹ã©ãã«ã®ãããªãã®ããããŸãããã®å Žåãä¿¡å·ã·ãŒã±ã³ã¹ã¯ãã¿ã³ãã¯è³ªãå°èäœçްèãé¢ããªããã°ãªããªãããšã瀺ããŠã ãŸããã¹ã¿ãŒãã¬ãã¯ã§ããããã®ãããªã¯ãŒã«ãªå°éçšèªã¯ãããŸããã§ããïŒ
ä¿¡å·ã·ãŒã±ã³ã¹ã¯ããã»ã©é·ãã¯ãããŸããããã³ãŒãäŸã¯ãŠã€ã«ã¹ã®RNAãšã¯ã¯ãã³ã®éãã瀺ããŠããŸããæ¯èŒããããããã«ãΚãRNAã®éåžžã®Uã«çœ®ãæããŸããã
3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
ãŠã€ã«ã¹ïŒAUG UUU GUU UUU CUU GUU UUA UUG CCA CUA GUC UCU AGU CAG UGU GUU
ã¯ã¯ãã³ïŒAUG UUC GUG UUC CUG GUG CUG CUG CCU CUG GUG UCC AGC CAG UGU GUU
ïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒïŒ
誀ã£ãŠRNAã3ã€ã®èšå·ã§ã°ã«ãŒãåããŠããªãããããã®ã·ã³ãã«ã¯ã³ãã³ã圢æããŸãããããŠãåã³ãã³ã¯ç¹å®ã®ã¢ããé žãã³ãŒãããŠããŸããã¯ã¯ãã³ã®ã·ã°ãã«é åã¯ããŠã€ã«ã¹èªäœãšãŸã£ããåãã¢ããé žã§æ§æãããŠããŸãã
RNAãéãã®ã¯ãªãã§ããïŒ RNAã«ã¯4ã€ã®ã·ã³ãã«ãããããã®ãã¡3ã€ãã³ãã³ãæ§æããããã
4 3 = 64ã®ã³ãã³ãååšããå¯èœæ§ããããŸã ãåæã«ã20ã®ç°ãªãã¢ããé žãããããŸãããããã€ãã®ã³ãã³ãåãã¢ããé žãã³ãŒãããŠããããšãããããŸãã
Lifeã¯ãRNAã³ãã³ãã¢ããé žã«ãããã³ã°ããããã«ã次ã®ã»ãŒæ®éçãªè¡šã䜿çšããŠããŸãã
ãã®è¡šã¯ãã¯ã¯ãã³ã®å€æŽïŒUUU-> UUCïŒãå矩ã§ããããšã瀺ããŠããŸããã¯ã¯ãã³ã®RNAã³ãŒãã¯ç°ãªããŸãããåºåã¯åãã¢ããé žãšã¿ã³ãã¯è³ªã§ãã
ç¶¿å¯ãªèª¿æ»ã«ãããã»ãšãã©ã®å€æŽã3ã§ããŒã¯ããã3çªç®ã®ã³ãã³ã«å«ãŸããŠããããšãããããŸãããŠãããŒãµã«ã³ãã³ããŒãã«ã確èªãããšããã®3çªç®ã®äœçœ®ãæçµçã«ååŸãããã¢ããé žã«åœ±é¿ãäžããªãããšããããããŸãã
ãããã倿Žãå矩ã§ããå Žåããªãããããå¿ èŠãªã®ã§ããïŒããèŠããšã1ã€ãé€ããŠãã¹ãŠå€æŽãããšãCãšGã®æ°ãå¢ã
ãŸãã ãªããããå¿ èŠãªã®ã§ããïŒãã§ã«è¿°ã¹ãããã«ãç§ãã¡ã®å ç«ã·ã¹ãã ã¯ãå€éšãRNAãã€ãŸã现èå€ããæ¥ãã³ãŒãã«å¯ŸããŠéåžžã«æççã§ããæ€åºãåé¿ããããã«ããã§ã«UãΚã«çœ®ãæããŠããŸãã
ããããGãšCã倧éã«å«ãRNAã¯ãããé »ç¹ã«ãããå¹ççã«ã¿ã³ãã¯è³ªã«å€æãããããšãããããŸããããã®ç®çã®ããã«ãRNAã¯ã¯ãã³ã®å€ãã®èšå·ã¯ãå¯èœãªå Žåã¯GãšCã«çœ®ãæããããŠããŸãã
æ¬ç©ã®ãªã¹ã®ãšã
ã¯ã¯ãã³ã®æ¬¡ã®3777RNAæåããCãšGã远å ããããšãç®çãšããŠããã³ãã³æé©åããããŠããŸããããã§ã¯ã³ãŒãå šäœã瀺ããŸãããããã®1ã€ã®ç¹å¥ãªãã©ã°ã¡ã³ãã調ã¹ãŸããã¯ã¯ãã³ãå¹ãã®ã¯åœŒã®ãããã§ã-ç§ãã¡ãéåžžã®çæŽ»ã«æ»ãã®ãå©ããã®ã¯ãã®éšåã§ãïŒ
* *
LDKVEAEVQIDRLITG
ãŠã€ã«ã¹ïŒCUU GAC AAA GUU GAG GCU GAA GUG CAA AUU GAU AGG UUG AUC ACA GGC
ã¯ã¯ãã³ïŒCUG GAC CCU CCU GAG GCC GAG GUG CAG AUC GAC AGA CUG AUC ACA GGC
LDPPEAEVQIDRLITG
ïŒ!!! !! ïŒïŒïŒïŒïŒïŒïŒ
ããã§ããéåžžã®å矩ã®RNAã®å€åãèŠãããŸããããšãã°ãæåã®ã³ãã³ã§ã¯ãCUUã¯CUGã«çœ®ãæããããŸãããããã«ãããã¯ã¯ãã³ã«å¥ã®Gã远å ãããã¿ã³ãã¯è³ªã®çæãä¿é²ãããŸããCUUãšCUGã¯ã¢ããé žLãã€ãŸããã€ã·ã³ãã³ãŒãããŠãããããã¿ã³ãã¯è³ªã«å€åã¯ãããŸããã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªãã¯ã¯ãã³ãšæ¯èŒããããšã«ããã2ã€ãé€ããŠãã¹ãŠã®å€æŽãåæ§ã«å矩ã§ããããšãããããŸãããããã®äž¡æ¹ããã®ãã©ã°ã¡ã³ãã«è¡šç€ºãããŸãã
3çªç®ãš4çªç®ã®ã³ãã³ã«ã¯å®éã®å€åãå«ãŸããŠããŸããã¢ããé žKããã³Vã¯ãPãŸãã¯ãããªã³ã«çœ®ãæããããŸããKã®å Žåã¯3åïŒ '!!!'ïŒãVã®å Žåã¯2åïŒ '!!'ïŒå€æŽããŸããããããã®2ã€ã®å€æŽã«ãããã¯ã¯ãã³ãéåžžã«åŒ·åãããããšãããããŸããã
ã§ã¯ãããã§äœãèµ·ãã£ãŠããã®ã§ãããããå®éã®ãŠã€ã«ã¹ç²åãèŠããšãã¹ãã€ã¯ã¿ã³ãã¯è³ªãæ£ã®æã§ããããšãããããŸãã
ã¹ãã€ã¯ã¯ãŠã€ã«ã¹ã®æ¬äœã«ä»çããŠããŸãïŒããã¯ã¬ãªã«ãã·ãã¿ã³ãã¯è³ªãïŒãããããç§ãã¡ã®ã¯ã¯ãã³ã¯ãããã®ãšããèªåã§çæããã ãã§ããããŠã€ã«ã¹äœã«ã¯ä»çããŸããã
å¥ã ã«ååšããã¹ãã€ã¯ã¿ã³ãã¯è³ªãå®å šã«ç°ãªãæ§é ã«åŽ©å£ããããšã倿ããŸãããããããã¯ã¯ãã³ã®äžéšãšããŠå°å ¥ãããå Žåãç§ãã¡ã®äœã¯ãããã«å¯Ÿããå ç«ãçºéãããã§ããã-ããããããã®åŽ©å£ããçš®é¡ã«å¯ŸããŠã®ã¿ãæ¬ç©ã®ã³ãããŠã€ã«ã¹ã¯ãŸã£ãããªã¹ãã€ã¯ãèªç€ºããŸãããã®åœ¢åŒã§ã¯ãã¯ã¯ãã³ã¯ã»ãšãã©æ©èœããŸããã
ã§ã¯ãç§ãã¡ã¯äœãããŠããã®ã§ããããïŒ 2017幎ã«ãã ã説æãããŸããé©åãªå Žæã§ã®ãããªã³ã®äºé眮æã«ããããŠã€ã«ã¹ã«ä»çããŠããªããŠããSARS-CoV-1ããã³MERSSã¿ã³ãã¯è³ªããå ã®ã圢ããšãæ¹æ³ããã¹ãŠãããªã³ã®åŒ·ãã«æè¬ããŸãããã®ã¢ããé žã¯ã¹ããªã³ãã®ããã«æ©èœããå ç«ç³»ã«æç€ºããå¿ èŠãããç¶æ ã§ã¿ã³ãã¯è³ªãå®å®ãããŸãã ãã ã
çºèŠãã人ã ã¯ãåžžã«è©ã軜ãããããåžžã«ãã€ãªãšç¬ãå¿ èŠããããŸãããããŠãããã¯ãã¹ãŠåœç¶ã®ããšã§ãã
èšäºã®æåã®ãã©ãããå ¬éãããåŸãç§ã¯ãã¯ã¬ã€ã©ã³ã®ç 究宀ã®äººã ãšè©±ãããŸããããããŠåœŒãã¯ãããŸã§ãã³ãããã¯ã®ããã«è©ã®ææãäžæããããšèšããŸãããããã圌ãã¯ã¯ã¯ãã³ãžã®åœŒãã®è²¢ç®ãèªãã«æã£ãŠããŸãããããŠãããã«åãçµãã§ããä»ã®ã°ã«ãŒãããã©ã³ãã£ã¢ã®éèŠæ§ã匷調ããŸãã
ãªã¹ã®çµãããšæ¬¡ã®ã¹ããã
ãœãŒã¹ã³ãŒããæåŸãŸã§ã¹ã¯ããŒã«ãããšãã¹ãã€ã¯ã¿ã³ãã¯è³ªã®æåŸã«å°ããªå€åãèŠãããŸãã
VLKGVKLHYT s
ãŠã€ã«ã¹ïŒGUG CUC AAA GGA GUC AAA UUA CAU UAC ACA UAA
ã¯ã¯ãã³ïŒGUG CUG AAG GGC GUG AAA CUG CAC UAC ACA UGA UGA
VLKGVKLHYT ss
ïŒïŒïŒïŒïŒïŒïŒïŒ
ã¿ã³ãã¯è³ªã®çµããã«ã¯ãæåsã§ããŒã¯ãããã忢ãã³ãã³ããããŸããããã¯ãã¿ã³ãã¯è³ªã®çµããã瀺ãäžå¯§ãªæ¹æ³ã§ãããŠã€ã«ã¹èªäœã¯UAAã³ãã³ã忢ãšããŠäœ¿çšããã¯ã¯ãã³ã¯2ã€ã®UGAã³ãã³ã䜿çšããŸãããããã念ã®ããã
æªç¿»èš³ãšãªã¢3 '
5 'ã®çµããã«ãªããœãŒã ã¬ã€ãã³ã¹ã«å¿ èŠãª5'-UTRãèŠã€ãã£ãã®ãšåãããã«ãã¿ã³ãã¯è³ªã®çµããã«åæ§ã®ã³ã³ã¹ãã©ã¯ãã§ãã3'-UTRãèŠã€ãããŸããã
圌女ã«ã€ããŠæžãèšèã¯ãããããããŸããããŠã£ãããã£ã¢ããåŒçšããããšæããŸãã ã3'-UTRã¯éºäŒåçºçŸã«ãããŠéèŠãªåœ¹å²ãæãããmRNAã®å±åšåãå®å®æ§ã茞åºããã³ç¿»èš³å¹çã«åœ±é¿ãäžããŸãã 3'-NTOã«é¢ããçŸåšã®ãã¹ãŠã®ç¥èã«ããããããããããã®äœæ¥ã¯äŸç¶ãšããŠå€§éšåãç¥ç§çã§ããã
ãã ããç¹å®ã®3'-UTRãã¿ã³ãã¯è³ªçºçŸã®åªä»ã«éåžžã«æåããŠããããšã¯ããã£ãŠããŸããWHOã®ææžã«ãããšãBioNTech / Pfizerã¯ã¯ãã³ã«å«ãŸãã3'-UTRã¯ããRNAã®å®å®æ§ãšé«ãç·ã¿ã³ãã¯è³ªçºçŸã確ä¿ããããã®åæïŒAESïŒmRNAããã³ããã³ã³ããªã¢ã«ã³ãŒãããã12SãªããœãŒã RNAã®ã¢ããæ«ç«¯ãšã³ãã³ãµãŒãã«ç±æ¥ããŸããç§ã¯äœãèšãããšãã§ããŸã-ãããã£ãã
ãããŠæåŸã«ãAAAAAAAAAAAAAAAAAAAAAAA
mRNAã®æåŸã¯ ããªã¢ããã«åãããŠããŸããããã¯AAAAAAAAAAAAAAAAAAAæååã®æã§çµãããšããè¯ãããªèšãæ¹ã§ããã©ãããã2020幎ãmRNAãåãåºããã
mRNAã¯äœåºŠãåå©çšã§ããŸãããæåŸããããã€ãã®ãAãã倱ãããŸãããAãããªããªããšããã«ãmRNAã¯æ©èœã忢ããç Žæ£ãããŸãããã®æå³ã§ãããªAããŒã«ã¯å£åããä¿è·ããŸããmRNAã¯ã¯ãã³ã®æåŸã®ãAãã®æé©éãæ±ºå®ããããã«ç¹å¥ãªç ç©¶ãè¡ãããŸããããªãŒãã³ãœãŒã¹ã§ã¯ã120åçšåºŠã«ãªã£ãŠãããšèªãã ã
BNT162b2ã¯ã¯ãã³ã¯ã§çµäºããŸã
****** **** UAGCAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAGCAUAU GACUAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAA
30ãAããæ¬¡ã«ããã¯ã¬ãªãããªã³ã«ãŒ-10ãïŒGCAUAUGACUïŒãç¶ããŠããã«70ãAãã
ã¿ã³ãã¯è³ªã®çºçŸãæ¹åããããã«ãç¬èªã®æé©åãåã³äœ¿çšãããŠããã®ã§ã¯ãªãããšæããŸãã
çµæ
ããã§ãBNT162b2ã¯ã¯ãã³ã®æ£ç¢ºãªå 容ãããããã»ãšãã©ã®å Žåããã®ããã«æ©èœããçç±ãããããŸããã
- RNAãéåžžã®mRNAã®ããã«èŠããããã®CAPãã£ããã
- ããç¥ãããŠããããã¹ããšæé©åã«æåãã5'-NTOã
- ã¹ãã€ã¯ã¿ã³ãã¯è³ªãé©åãªå Žæã«éä¿¡ããæé©åãããã³ãã³ãæã€ä¿¡å·ã·ãŒã±ã³ã¹ïŒãŠã€ã«ã¹èªäœããã³ããŒïŒã
- æé©åãããã³ãã³ãæã€å ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ããªã¢ã³ãã§ãæ£ããèæ€ã®åœ¢ç¶ã確ä¿ããããã«2ã€ã®ãããªã³çœ®æããããŸãã
- ããç¥ãããŠããããã¹ããšæé©åã«æåãã3'-NTOã
- ããçš®ã®ããªã³ã«ãŒããåããããªAã®å°ãäžæè°ãªå°Ÿã
ã³ãã³ãæé©åãããšãmRNAã«å€ãã®GãšCã远å ãããŸããUã®ä»£ããã«ÎšïŒ1-ã¡ãã«-3'-ã·ã¥ãŒããŠãªãžã³ïŒã䜿çšãããšãå ç«ã·ã¹ãã ãã ãŸãã®ã«åœ¹ç«ã¡ãŸãããã®ãããã§ãmRNAã¯ç§ãã¡ã®å ç«ã·ã¹ãã ãèšç·Žããã®ã«ååãªé·ãã§ååšããŸãã